Substance Use Disorders and Health Management

A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Public Health and Preventive Medicine".

Deadline for manuscript submissions: 10 March 2027 | Viewed by 304

Editors


E-Mail Website
Guest Editor
Center for Behavioral Emergency & Addiction Research, McWilliams School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX 77030, USA
Interests: health services research; community engagement; public health law

E-Mail Website
Guest Editor Assistant
Center for Behavioral Emergency & Addiction Research, McWilliams School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX 77030, USA
Interests: opioids; opioid use disorder; health care policy; health care management; healthcare quality; health outcomes

Special Issue Information

Dear Colleagues,

Substance use disorder (SUD) is a major driver of preventable morbidity and mortality and a growing challenge for health systems. Across emergency departments, hospitals, primary care, and community settings, organizations are increasingly responsible for delivering evidence-based SUD services while navigating fragmented healthcare reimbursement, variable regulations, and uneven clinical capacity. These system conditions influence access, care continuity, treatment quality, and patient outcomes including stigma.

As the literature suggests, strong heterogeneity exists in how health systems design, implement, and evaluate SUD services. This variation is often shaped by policy context such as Medicaid design and eligibility changes, behavioral health carve-outs, reimbursement rules for medication for opioid use disorder (MOUD) and counseling, telehealth flexibilities, and parity implementation. While policy variation can enable local innovation, it also creates uneven access and inconsistent standards of care across jurisdictions and payer environments. Healthcare organizations face conflicting incentives, reimbursement, and incomplete guidance when deciding what to implement for SUD services. This may impact service delivery, how to finance service delivery, and how to measure performance, limiting comparability and slowing cumulative learning.

We are pleased to invite you to provide empirical studies, implementation and quality improvement reports, and state-of-the-art reviews that identify actionable healthcare management and policy levers for scalable SUD care. We welcome submissions on integrated care, equity-focused delivery, data/analytics, telehealth, policy and cross-sector partnerships, healthcare service financing and sustainability, healthcare workforce and leadership that improve real-world outcomes.

This Special Issue aims to publish original research and reviews on how healthcare management and policy contexts shape the implementation and evaluation of evidence-based substance use disorder (SUD) services across care settings. Submissions may include implementation and quality improvement studies, health services and outcomes research, organizational and workforce analyses, and policy evaluations examining state variation (e.g., parity implementation, telehealth/prescribing rules, and PDMP requirements), financial impact on health services or patients. We welcome narrative and systematic reviews, scoping reviews, and meta-analyses that synthesize management and policy levers linked to access, retention, equity, and real-world SUD outcomes.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Systematic reviews/meta-analyses on management and policy levers in SUD care.
  • Implementation and QI studies of evidence-based SUD models (e.g., MOUD, integrated care).
  • SUD outcomes studies of organizational factors for healthcare organizations (workforce, leadership, readiness).
  • Healthcare financing and payment analyses for care models (e.g., Medicaid/1115 waivers, parity, value-based care).
  • Legal epidemiological policy comparisons across states/payers (telehealth/prescribing rules, PDMPs, etc.).

We look forward to receiving your contributions.

Prof. Dr. James R. Langabeer
Guest Editor

Dr. Francine R. Vega
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • substance use disorder (SUD)
  • healthcare management
  • health policy
  • medication for opioid use disorder (MOUD)
  • integrated care
  • implementation science
  • quality improvement
  • Medicaid
  • telehealth

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 531 KB  
Article
Prescription Opioid Misuse Among High School Athletes During the Opioid Prescribing Limit Law Era: YRBSS 2017–2023
by Francine R. Vega, Andrea J. Yatsco, Audrey Sarah Cohen, James R. Langabeer, Tiffany Champagne-Langabeer, Rakshitha Vijendra and Christine Bakos-Block
Healthcare 2026, 14(15), 2407; https://doi.org/10.3390/healthcare14152407 - 5 Aug 2026
Abstract
Background/Objectives: School-age athletes occupy a paradoxical position in the adolescent opioid crisis, combining health-oriented activity with elevated risk of sports-related injury and prescription opioid exposure. In response to the opioid epidemic, states enacted opioid prescribing limit laws (OPLLs) beginning in 2016–2017, yet whether [...] Read more.
Background/Objectives: School-age athletes occupy a paradoxical position in the adolescent opioid crisis, combining health-oriented activity with elevated risk of sports-related injury and prescription opioid exposure. In response to the opioid epidemic, states enacted opioid prescribing limit laws (OPLLs) beginning in 2016–2017, yet whether these supply-side policies reached high-risk youth subgroups remains unclear. This study evaluated national temporal trends in prescription opioid misuse among U.S. high school students during the period of OPLL implementation and examined differences across athletic participation, concussion history, sex, grade, race/ethnicity, and substance-use profiles. Methods: Using four biennial waves of the Youth Risk Behavior Surveillance System with a consistent prescription pain-medicine measure (2017, 2019, 2021, and 2023; total N = 44,501), we conducted survey-weighted multivariable logistic regression models producing adjusted odds ratios (aORs) for lifetime prescription opioid misuse, controlling for survey year, sports participation, sex, grade, race/ethnicity, alcohol use, and other illicit drug use. Interaction and stratified models examined differences associated with sports participation, concussion history, demographic characteristics, and substance use. Results: Weighted prescription opioid misuse declined from 13.9% in 2017 to 12.0% in 2023, with a significant unadjusted linear decline per two-year survey wave (OR = 0.936; 95% CI: 0.879–0.997; p = 0.040). This overall trend was attenuated after adjustment (aOR = 0.967; 95% CI: 0.914–1.024; p = 0.248). Temporal patterns differed significantly across race/ethnicity, sex, grade, and selected substance-use groups. White and male students demonstrated significant adjusted linear declines, whereas Hispanic/Latino and female students remained flat. Black/African American students showed significant year-to-year variation, with elevated adjusted odds in 2019 and 2021 relative to 2017. Concussion history was independently associated with misuse among athletes (aOR = 1.645; 95% CI: 1.417–1.909; p < 0.001), with significant associations observed among White, Asian, Black/African American, and Hispanic/Latino athletes. The pooled concussion-by-race/ethnicity interaction, however, was not significant (p = 0.295). Conclusions: Although prescription opioid misuse declined descriptively between 2017 and 2023, adjusted analyses did not identify a significant overall national temporal change. Since subgroup patterns diverged, prevention planning and surveillance should be disaggregated by race/ethnicity and sex rather than guided by national totals, and groups whose misuse did not decline may require strategies extending beyond clinical prescribing controls. Full article
(This article belongs to the Special Issue Substance Use Disorders and Health Management)
Show Figures

Figure 1

Back to TopTop